250 related articles for article (PubMed ID: 9361572)
1. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
[TBL] [Abstract][Full Text] [Related]
2. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
4. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
[TBL] [Abstract][Full Text] [Related]
5. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Harenberg J; Ingrid J; Tivadar F
Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
[TBL] [Abstract][Full Text] [Related]
7. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Prandoni P; Carnovali M; Marchiori A;
Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
[TBL] [Abstract][Full Text] [Related]
9. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
[TBL] [Abstract][Full Text] [Related]
11. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
[TBL] [Abstract][Full Text] [Related]
12. Treatment of symptomatic venous thromboembolism: improving outcomes.
Büller HR
Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Kearon C
Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
[TBL] [Abstract][Full Text] [Related]
14. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
Hull R; Delmore T; Genton E; Hirsh J; Gent M; Sackett D; McLoughlin D; Armstrong P
N Engl J Med; 1979 Oct; 301(16):855-8. PubMed ID: 384248
[TBL] [Abstract][Full Text] [Related]
15. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Ciccarese M; Papaldo P; Fabi A; Cognetti F
Thromb Res; 2007; 119(4):525-9. PubMed ID: 16780933
[TBL] [Abstract][Full Text] [Related]
16. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
Vardi M; Laor A; Bitterman H
Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
[TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
18. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
Hull RD; Raskob GE; Hirsh J; Jay RM; Leclerc JR; Geerts WH; Rosenbloom D; Sackett DL; Anderson C; Harrison L
N Engl J Med; 1986 Oct; 315(18):1109-14. PubMed ID: 3531862
[TBL] [Abstract][Full Text] [Related]
19. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
[TBL] [Abstract][Full Text] [Related]
20. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
Hull RD; Raskob GE; Rosenbloom D; Panju AA; Brill-Edwards P; Ginsberg JS; Hirsh J; Martin GJ; Green D
N Engl J Med; 1990 May; 322(18):1260-4. PubMed ID: 2183055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
